摘要
目的:探讨贝伐株单抗联合伊立替康治疗晚期结直肠癌的疗效和安全性。方法:选择2016年7月—2018年1月治疗的晚期结直肠癌80例,按照治疗方案不同分为观察组40例和对照组40例。对照组采用FOLFIRI方案化疗。观察组在对照组的基础上,采取贝伐珠单抗治疗。观察两组血清血管内皮生长因子(VEGF)、金属蛋白酶-9(MMP-9)水平、疗效及不良反应发生情况。结果:观察组干预后血清VEGF、MMP-9水平低于干预前和对照组,差异有统计学意义(P<0.05);观察组总有效率为62.5%,高于对照组的25.0%,差异有统计学意义(P<0.05);两组不良反应发生情况对比,差异无统计学意义(P>0.05)。结论:晚期结直肠癌患者采取贝伐株单抗联合伊立替康治疗,患者血清VEGF、MMP-9水平改善较好,未增加患者不良反应发生风险。
Objective:To investigate the efficacy and safety of bevacizumab combined with irinotecan in the treatment of advanced colorectal cancer.Methods:The clinical data of 80 patients treated in our hospital from July 2016 to January 2018 were collected.The patients were divided into observation group(40 cases)and control group(40 cases).Control group:FOLFIRI regimen chemotherapy.On the basis of the control group,bevacizumab was used in observation group.Serum levels of vascular endothelial growth factor(VEGF),Matrix metalloproteinasc-9(MMP-9),efficacy and adverse reactions were observed.Results:The serum levels of vascular endothelial growth factor and MMP-9 in the observation group were lower than those before intervention and the control group,with significant difference(P<0.05);the total effective rate in the observation group was 62.5%,higher than that in the control group(25.0%,P<0.05);the occurrence of adverse reactions in the two groups was compared,there was no significient difference(P>0.05).Conclusion:Bevacizumab combined with irinotecan is effective in the treatment of advanced colorectal cancer.Serum levels of vascular endothelial growth factor and MMP-9 in patients with advanced colorectal cancer are improved,and the risk of adverse reactions is not increased.
作者
梁小芳
刘煌
李丽华
江健
LIANG Xiaofang;LIU Huang;LI Lihua;JIANG Jian(People's Hospital of Yichun City,Yichun 336000,China)
出处
《临床医药实践》
2019年第10期723-725,共3页
Proceeding of Clinical Medicine
